Drug Discovery

BridGene raises $38.5m to develop IMTAC platform and cancer drugs

BridGene Biosciences has raised $38.5m in Series B financing round for the development of its next generation chemoproteomic platform, Isobaric Mass Tagged Affinity Characterization (IMTAC), as well as oncology drugs.

QBiotics receives IND application approval for Phase II solid tumours therapy trial

The US Food and Drug Administration (FDA) has approved QBiotics Group’s Investigational New Drug (IND) application to commence the Phase II clinical trial (QB46C-H07) of tigilanol tiglate.

SRI, Amylyx Pharmaceuticals partner to identify ALS drug candidates

Sunnybrook Research Institute (SRI) and Amylyx Pharmaceuticals have joined forces to develop new drug candidates to treat amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

SK Biopharmaceuticals, Eurofarma sign deal for epilepsy therapy

SK Biopharmaceuticals and Brazilian pharmaceutical firm Eurofarma have signed a license agreement to develop and commercialise cenobamate to treat epilepsy in Latin America.

Orion Biotechnology Canada, Peptilogics enter research and development collaboration

Orion Biotechnology Canada, and Peptilogics have entered a research and development collaboration to leverage artificial intelligence (AI) for drug discovery against an undrugged G Protein-Coupled Receptors (GPCRs) target.

Inspirna raises funds to advance clinical stage cancer drugs development

Inspirna has raised $50m in Series D financing round to advance the development of its clinical stage cancer drugs.

WuXi XDC, AbTis sign MoU to develop ADC products

WuXi XDC has signed a Memorandum of Understanding (MOU) with Korean biotechnology firm AbTis to develop and manufacture a portfolio of antibody-drug conjugates (ADC) products.

Exelixis, Ryvu Therapeutics to develop new targeted cancer therapies

Exelixis has signed an exclusive license agreement with Ryvu Therapeutics to develop new targeted cancer therapies.

Turnstone, Moffitt Cancer Center partner to develop TIL cell therapies

Turnstone Biologics has formed a broad strategic alliance with Moffitt Cancer Center for advancing the development of next-generation tumour-infiltrating lymphocyte (TIL) therapies for solid tumours.